Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

INSP vs NVCR vs TNDM vs IRTC vs MDT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
INSP
Inspire Medical Systems, Inc.

Medical - Devices

HealthcareNYSE • US
Market Cap$1.31B
5Y Perf.-44.1%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-75.0%
TNDM
Tandem Diabetes Care, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$1.27B
5Y Perf.-77.8%
IRTC
iRhythm Technologies, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$4.10B
5Y Perf.+0.5%
MDT
Medtronic plc

Medical - Devices

HealthcareNYSE • IE
Market Cap$99.94B
5Y Perf.-20.9%

INSP vs NVCR vs TNDM vs IRTC vs MDT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
INSP logoINSP
NVCR logoNVCR
TNDM logoTNDM
IRTC logoIRTC
MDT logoMDT
IndustryMedical - DevicesMedical - Instruments & SuppliesMedical - DevicesMedical - DevicesMedical - Devices
Market Cap$1.31B$1.92B$1.27B$4.10B$99.94B
Revenue (TTM)$915M$674M$1.03B$788M$35.48B
Net Income (TTM)$131M$-173M$-95M$-28M$4.61B
Gross Margin85.8%75.2%54.9%71.0%61.9%
Operating Margin5.6%-27.2%-7.9%-3.3%17.9%
Forward P/E24.5x14.1x
Total Debt$32M$290M$444M$731M$28.52B
Cash & Equiv.$105M$103M$91M$236M$2.22B

INSP vs NVCR vs TNDM vs IRTC vs MDTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

INSP
NVCR
TNDM
IRTC
MDT
StockMay 20May 26Return
Inspire Medical Sys… (INSP)10055.9-44.1%
NovoCure Limited (NVCR)10025.0-75.0%
Tandem Diabetes Car… (TNDM)10022.2-77.8%
iRhythm Technologie… (IRTC)100100.5+0.5%
Medtronic plc (MDT)10079.1-20.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: INSP vs NVCR vs TNDM vs IRTC vs MDT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MDT leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Inspire Medical Systems, Inc. is the stronger pick specifically for profitability and margin quality. NVCR and IRTC also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
INSP
Inspire Medical Systems, Inc.
The Growth Play

INSP is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.

  • Rev growth 13.6%, EPS growth 179.4%, 3Y rev CAGR 30.8%
  • Lower volatility, beta 1.27, Low D/E 4.1%, current ratio 6.08x
  • 14.3% margin vs NVCR's -25.7%
Best for: growth exposure and sleep-well-at-night
NVCR
NovoCure Limited
The Momentum Pick

NVCR ranks third and is worth considering specifically for momentum.

  • +1.1% vs INSP's -70.9%
Best for: momentum
TNDM
Tandem Diabetes Care, Inc.
The Healthcare Pick

Among these 5 stocks, TNDM doesn't own a clear edge in any measured category.

Best for: healthcare exposure
IRTC
iRhythm Technologies, Inc.
The Long-Run Compounder

IRTC is the clearest fit if your priority is long-term compounding and defensive.

  • 379.3% 10Y total return vs INSP's 82.4%
  • Beta 0.93, current ratio 4.63x
  • 26.2% revenue growth vs MDT's 3.6%
Best for: long-term compounding and defensive
MDT
Medtronic plc
The Income Pick

MDT carries the broadest edge in this set and is the clearest fit for income & stability.

  • Dividend streak 36 yrs, beta 0.47, yield 3.6%
  • Better valuation composite
  • Beta 0.47 vs NVCR's 2.20, lower leverage
  • 3.6% yield; 36-year raise streak; the other 4 pay no meaningful dividend
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthIRTC logoIRTC26.2% revenue growth vs MDT's 3.6%
ValueMDT logoMDTBetter valuation composite
Quality / MarginsINSP logoINSP14.3% margin vs NVCR's -25.7%
Stability / SafetyMDT logoMDTBeta 0.47 vs NVCR's 2.20, lower leverage
DividendsMDT logoMDT3.6% yield; 36-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)NVCR logoNVCR+1.1% vs INSP's -70.9%
Efficiency (ROA)MDT logoMDT175.8% ROA vs NVCR's -16.5%, ROIC 6.0% vs -16.4%

INSP vs NVCR vs TNDM vs IRTC vs MDT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

INSPInspire Medical Systems, Inc.
FY 2025
Operating Segment
100.0%$912M
NVCRNovoCure Limited

Segment breakdown not available.

TNDMTandem Diabetes Care, Inc.
FY 2025
Supplies and Other
54.3%$551M
Pump
45.7%$464M
IRTCiRhythm Technologies, Inc.
FY 2025
Commercial Payors
52.5%$392M
Centers For Medicare And Medicaid
24.0%$179M
Healthcare Institutions
16.8%$126M
Non-contracted Third-party Payors
6.7%$50M
MDTMedtronic plc
FY 2025
Cardiac and Vascular Group
37.3%$12.5B
Neuroscience Group
29.4%$9.8B
Medical Surgical
25.1%$8.4B
Diabetes Group
8.2%$2.8B

INSP vs NVCR vs TNDM vs IRTC vs MDT — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLINSPLAGGINGMDT

Income & Cash Flow (Last 12 Months)

Evenly matched — INSP and MDT each lead in 2 of 6 comparable metrics.

MDT is the larger business by revenue, generating $35.5B annually — 52.6x NVCR's $674M. INSP is the more profitable business, keeping 14.3% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, IRTC holds the edge at +25.7% YoY revenue growth, suggesting stronger near-term business momentum.

MetricINSP logoINSPInspire Medical S…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…IRTC logoIRTCiRhythm Technolog…MDT logoMDTMedtronic plc
RevenueTrailing 12 months$915M$674M$1.0B$788M$35.5B
EBITDAEarnings before interest/tax$62M-$165M-$68M-$6M$9.4B
Net IncomeAfter-tax profit$131M-$173M-$95M-$28M$4.6B
Free Cash FlowCash after capex$97M-$48M-$4M$19M$5.4B
Gross MarginGross profit ÷ Revenue+85.8%+75.2%+54.9%+71.0%+61.9%
Operating MarginEBIT ÷ Revenue+5.6%-27.2%-7.9%-3.3%+17.9%
Net MarginNet income ÷ Revenue+14.3%-25.7%-9.2%-3.5%+13.0%
FCF MarginFCF ÷ Revenue+10.6%-7.1%-0.4%+2.4%+15.2%
Rev. Growth (YoY)Latest quarter vs prior year+1.6%+12.3%+5.5%+25.7%+8.8%
EPS Growth (YoY)Latest quarter vs prior year-5.0%-100.0%+84.8%+55.7%-11.9%
Evenly matched — INSP and MDT each lead in 2 of 6 comparable metrics.

Valuation Metrics

Evenly matched — INSP and MDT each lead in 2 of 6 comparable metrics.

At 9.3x trailing earnings, INSP trades at a 57% valuation discount to MDT's 21.6x P/E. On an enterprise value basis, MDT's 14.3x EV/EBITDA is more attractive than INSP's 19.1x.

MetricINSP logoINSPInspire Medical S…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…IRTC logoIRTCiRhythm Technolog…MDT logoMDTMedtronic plc
Market CapShares × price$1.3B$1.9B$1.3B$4.1B$99.9B
Enterprise ValueMkt cap + debt − cash$1.2B$2.1B$1.6B$4.6B$126.2B
Trailing P/EPrice ÷ TTM EPS9.32x-13.80x-6.08x-89.83x21.60x
Forward P/EPrice ÷ next-FY EPS est.24.46x14.13x
PEG RatioP/E ÷ EPS growth rate36.00x
EV / EBITDAEnterprise value multiple19.11x14.32x
Price / SalesMarket cap ÷ Revenue1.44x2.92x1.25x5.49x2.98x
Price / BookPrice ÷ Book value/share1.74x5.51x8.01x26.16x2.08x
Price / FCFMarket cap ÷ FCF16.73x118.84x19.28x
Evenly matched — INSP and MDT each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

INSP leads this category, winning 6 of 9 comparable metrics.

INSP delivers a 18.0% return on equity — every $100 of shareholder capital generates $18 in annual profit, vs $-68 for TNDM. INSP carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to IRTC's 4.79x. On the Piotroski fundamental quality scale (0–9), INSP scores 7/9 vs TNDM's 3/9, reflecting strong financial health.

MetricINSP logoINSPInspire Medical S…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…IRTC logoIRTCiRhythm Technolog…MDT logoMDTMedtronic plc
ROE (TTM)Return on equity+18.0%-50.8%-68.3%-20.6%+9.4%
ROA (TTM)Return on assets+15.2%-16.5%-10.0%-2.8%+175.8%
ROICReturn on invested capital+6.0%-16.4%-10.0%-5.2%+6.0%
ROCEReturn on capital employed+6.7%-28.9%-11.5%-4.4%+7.5%
Piotroski ScoreFundamental quality 0–975366
Debt / EquityFinancial leverage0.04x0.85x2.86x4.79x0.59x
Net DebtTotal debt minus cash-$73M$187M$354M$495M$26.3B
Cash & Equiv.Liquid assets$105M$103M$91M$236M$2.2B
Total DebtShort + long-term debt$32M$290M$444M$731M$28.5B
Interest CoverageEBIT ÷ Interest expense418.58x-96.80x-15.99x-1.48x9.08x
INSP leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

IRTC leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in IRTC five years ago would be worth $15,609 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, NVCR leads with a +1.1% total return vs INSP's -70.9%. The 3-year compound annual growth rate (CAGR) favors IRTC at -0.7% vs INSP's -45.6% — a key indicator of consistent wealth creation.

MetricINSP logoINSPInspire Medical S…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…IRTC logoIRTCiRhythm Technolog…MDT logoMDTMedtronic plc
YTD ReturnYear-to-date-50.6%+28.3%-14.3%-28.7%-18.1%
1-Year ReturnPast 12 months-70.9%+1.1%-17.0%-8.3%-2.8%
3-Year ReturnCumulative with dividends-83.9%-75.7%-44.8%-2.1%-4.2%
5-Year ReturnCumulative with dividends-76.6%-91.3%-78.0%+56.1%-27.7%
10-Year ReturnCumulative with dividends+82.4%+30.3%-75.4%+379.3%+26.5%
CAGR (3Y)Annualised 3-year return-45.6%-37.6%-18.0%-0.7%-1.4%
IRTC leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — NVCR and MDT each lead in 1 of 2 comparable metrics.

MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs INSP's 27.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricINSP logoINSPInspire Medical S…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…IRTC logoIRTCiRhythm Technolog…MDT logoMDTMedtronic plc
Beta (5Y)Sensitivity to S&P 5001.27x2.20x1.45x0.93x0.47x
52-Week HighHighest price in past year$163.35$20.06$29.65$212.00$106.33
52-Week LowLowest price in past year$44.41$9.82$9.98$112.31$77.16
% of 52W HighCurrent price vs 52-week peak+27.9%+83.9%+62.3%+58.9%+73.3%
RSI (14)Momentum oscillator 0–10031.669.839.144.127.3
Avg Volume (50D)Average daily shares traded1.1M1.5M1.8M524K7.8M
Evenly matched — NVCR and MDT each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: INSP as "Hold", NVCR as "Buy", TNDM as "Buy", IRTC as "Buy", MDT as "Buy". Consensus price targets imply 100.4% upside for INSP (target: $91) vs 40.5% for MDT (target: $110). MDT is the only dividend payer here at 3.57% yield — a key consideration for income-focused portfolios.

MetricINSP logoINSPInspire Medical S…NVCR logoNVCRNovoCure LimitedTNDM logoTNDMTandem Diabetes C…IRTC logoIRTCiRhythm Technolog…MDT logoMDTMedtronic plc
Analyst RatingConsensus buy/hold/sellHoldBuyBuyBuyBuy
Price TargetConsensus 12-month target$91.33$33.50$31.62$193.67$109.50
# AnalystsCovering analysts2715391949
Dividend YieldAnnual dividend ÷ price+3.6%
Dividend StreakConsecutive years of raises36
Dividend / ShareAnnual DPS$2.78
Buyback YieldShare repurchases ÷ mkt cap+13.3%0.0%0.0%0.0%+3.2%
Insufficient data to determine a leader in this category.
Key Takeaway

INSP leads in 1 of 6 categories (Profitability & Efficiency). IRTC leads in 1 (Total Returns). 3 tied.

Best OverallInspire Medical Systems, In… (INSP)Leads 1 of 6 categories
Loading custom metrics...

INSP vs NVCR vs TNDM vs IRTC vs MDT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is INSP or NVCR or TNDM or IRTC or MDT a better buy right now?

For growth investors, iRhythm Technologies, Inc.

(IRTC) is the stronger pick with 26. 2% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Inspire Medical Systems, Inc. (INSP) offers the better valuation at 9. 3x trailing P/E (24. 5x forward), making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — INSP or NVCR or TNDM or IRTC or MDT?

On trailing P/E, Inspire Medical Systems, Inc.

(INSP) is the cheapest at 9. 3x versus Medtronic plc at 21. 6x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — INSP or NVCR or TNDM or IRTC or MDT?

Over the past 5 years, iRhythm Technologies, Inc.

(IRTC) delivered a total return of +56. 1%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: IRTC returned +379. 3% versus TNDM's -75. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — INSP or NVCR or TNDM or IRTC or MDT?

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

47β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 373% more volatile than MDT relative to the S&P 500. On balance sheet safety, Inspire Medical Systems, Inc. (INSP) carries a lower debt/equity ratio of 4% versus 5% for iRhythm Technologies, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — INSP or NVCR or TNDM or IRTC or MDT?

By revenue growth (latest reported year), iRhythm Technologies, Inc.

(IRTC) is pulling ahead at 26. 2% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Inspire Medical Systems, Inc. grew EPS 179. 4% year-over-year, compared to -106. 8% for Tandem Diabetes Care, Inc.. Over a 3-year CAGR, INSP leads at 30. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — INSP or NVCR or TNDM or IRTC or MDT?

Inspire Medical Systems, Inc.

(INSP) is the more profitable company, earning 15. 9% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 15. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDT leads at 17. 8% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — INSP leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is INSP or NVCR or TNDM or IRTC or MDT more undervalued right now?

On forward earnings alone, Medtronic plc (MDT) trades at 14.

1x forward P/E versus 24. 5x for Inspire Medical Systems, Inc. — 10. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for INSP: 100. 4% to $91. 33.

08

Which pays a better dividend — INSP or NVCR or TNDM or IRTC or MDT?

In this comparison, MDT (3.

6% yield) pays a dividend. INSP, NVCR, TNDM, IRTC do not pay a meaningful dividend and should not be held primarily for income.

09

Is INSP or NVCR or TNDM or IRTC or MDT better for a retirement portfolio?

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

47), 3. 6% yield). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +26. 5%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between INSP and NVCR and TNDM and IRTC and MDT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: INSP is a small-cap deep-value stock; NVCR is a small-cap quality compounder stock; TNDM is a small-cap quality compounder stock; IRTC is a small-cap high-growth stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while INSP, NVCR, TNDM, IRTC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

INSP

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 8%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

TNDM

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 32%
Run This Screen
Stocks Like

IRTC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 12%
  • Gross Margin > 42%
Run This Screen
Stocks Like

MDT

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform INSP and NVCR and TNDM and IRTC and MDT on the metrics below

Revenue Growth>
%
(INSP: 1.6% · NVCR: 12.3%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.